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Summary-A small group of institutionalized Down’s syndrome patients were treated 
with topical kanamycin sulphate paste, once or twice a day for 3-5 days, every fifth week 
over a 52-week-period. The teeth were not brushed during this 52-week-period. The wet 
weight of the supragingival plaque in the kanamycin group was significantly reduced 
when compared to the supragingival plaque formed in the group receiving a placebo 
paste. The gingivitis score of the kanamycin group did not deteriorate during the 
period of antibiotic administration despite the absence of oral hygiene procedures. 
No increase in kanamycin-resistant bacteria or yeasts were detected in plaque or 
tongue samples during the period of kanamycin treatment. 
INTRODUCTION 
MANY mentally handicapped, institutionalized children have bacterial plaque accumu- 
lations which lead to periodontal disease at an early age (BROWN, LEVIN and CUN- 
NINGHAM, 1961; SWALLOW, 1964; SZNAJDER et cd., 1968; LOESCHE et al., 1971; 
CUTRESS, 1971). This situation may be attributed to the fact that most of these indi- 
viduals are not capable of brushing their own teeth and that the dental manpower 
available at these institutions is not adequate to provide effective toothbrushing and 
prophylaxis of the residents. These difficulties are of sufficient magnitude that it is 
unlikely that they can be solved by conventional hygiene procedures, even allowing 
for a generous increase in capital to cover the cost of oral therapists. 
New approaches to the control of oral health in these handicapped individuals are 
needed. The recent experimental evidence that the mass of bacteria, which reside on the 
dental gingival surfaces, may be dependent upon the presence of specific plaque- 
forming organisms (GIBBONS et al., 1966; KRASSE et al., 1968; SOCRANSKY, HUBERSAK 
and PROPAS, 1970; JORDAN ~~~.HAMMOND, 1972) offers the possibility of a chemo- 
therapeutic approach aimed at the elimination of these specific bacteria (ENGLANDER 
and KEYES, 1971; JORDAN and DEPAOLA, 1972). With this in mind, a clinical trial of 
topical kanamycin as a means of improving oral health in mentally retarded indi- 
viduals was undertaken (LOESCHE et al., 1971). The results were partially successful 
in that a 5-day-treatment, in which kanamycin was applied to the dental gingival 
surfaces in the morning, afternoon and evening, had a residual effect that lasted 
between 4 and 8 weeks post-treatment. At 4 weeks post-treatment, in the absence of 
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any other oral hygiene procedures, the kanamycin had reduced supragingival plaque 
accumulations significantly and had lowered the gingivitis score from preantibiotic 
levels. The effect of the antibiotic disappeared with time. This study raised the question 
as to what effect retreatment with kanamycin would have on maintaining the oral 
health of these subjects. 
Subjects 
MATERIALS AND METHODS 
Down’s syndrome individuals institutionalized at the Plymouth State Home and Training School, 
Northville, Michigan, served as subjects. These individuals were residents in four wards of the same 
dormitory. Thirteen males and two females ranging in age from 7 to 14 yr were included in the study. 
They exhibited low caries prevalence, averaged about 4 mg of plaque per reference tooth, and had 
moderate to severe gingivitis. The subjects were randomly assigned to either the kanamycin or 
placebo group. However, data obtained from two children in the kanamycin group and one child 
in the placebo group were subsequently omitted from the calculations, as the ability of these children 
to form plaque and calculus differed markedly from the other subjects (Table 1). Certain subjects 
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received systemic antibiotics for medical purposes during the 52-week-period covered by this investi- 
gation. This treatment invariably improved the oral health of the subjects, and data obtained during 
these periods of medication were omitted from the calculations. On occasion, the subjects were not 
available for examination due to leave of absence, quarantines or attendance in class. These factors 
account for the variability in subject number shown in Table 2. 
Plaque andgingivitis measurements 
The six reference teeth (RAMFJORD, 1959), i.e. maxillary right first molar, maxillary left central 
incisor, maxillary left first premolar, mandibular left first molar, mandibular right central incisor 
and mandibular right first premolar were scored by a double-blind technique for plaque and gingivitis 
using modifications of the indices developed by L& (1967). The appearance of the plaque was used to 
estimate the range in which the score woutd fall, i.e. no plaque visible, &l ; small to moderate amounts 
of plaque visible, > 1-2; large amounts of plaque visible, > 2-3; and in rare instances, when the 
plaque was extremely thick and practically covered the entire tooth surface, a score of 4 was given. 
Then the amount of plaque removed by a periodontal scaler from the buccal or labial aspect of the 
tooth was subjectively evaluated, and used to assign the final score within that range. Plaque scores 
intermediate between the Lee indices were given, i.e. 1.5 and 2.5. The same two investigators scored 
each buccal or labial surface simultaneously. Agreement on the score was usually obtained but, if 
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kanamycin placebo 
1.4 zt 0.6 4.1 * 1.7 
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3.4 i 2.4 
NS: n = 10 
NS n = 10 
p = 0.01 n = 9 





* Reference teeth: 3, 9, 12, 19, 25, 28. 
t Student f-test. 
: Not significant. 
5 Mg wet weight plus or minus standard deviation. 
differences in opinion occurred, the values were averaged. The ability of this scoring system to 
reflect plaque mass was subsequently determined as the plaque which was removed from the reference 
teeth was pooled and weighed (Fig. 1). 
The modification of the gingivitis index again involved a consensus scoring system. When the 
investigators were not in agreement, an average of the two values was recorded. The score given 
was for the entire buccal-gingival or labial-gingival margin and did not involve the lingual gingiva. 
The amount of bleeding which occurred when the supragingival plaque was being removed was 
noted and used to formulate the gingivitis scores. In a few instances, the gingivitis was so severe that a 
score of 4 was given. 
F 
IO - . 
y=4.46x-4.73 . 
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FIG. 1. Correlation between plaque wet weight and unstained plaque score made on insti- 
tutionalized Down’s syndrome patients. 
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After the subjective scoring was complete, the supragingival plaque from the six teeth was trans- 
ferred from the scalers to a preweighed piece of aluminium foil. The wet weight of the plaque was 
determined within 1 min after collection, using a Roller Smith Precision Balance (Model L6) with a 
full scale reading of 100 mg. This scale is accurate to ho.05 mg. Delay in obtaining this reading was 
avoided, because the dehydration of the plaque would give erroneous plaque weights. Immediate wet 
weight determinations of plaque correlated significantly with plaque dry weights in this population, 
i.e. r = 0.92 (LOESCHE and GREEN, 1972). The weight of the pooled plaque sample was divided by the 
number of reference teeth to give an average weight per reference tooth. This value was used in the 
various calculations. 
Bateriological procedures 
Plaque samples and tongue swabs from each child were cultured at each 5-week examination period 
with few exceptions. The plaque and tongue swabs were each placed in 10 ml of a reduced transport 
fluid (RTF) containing 0.02 per cent dithiothreitol (DTT) and OG)l M ethylenediamine tetra acetic 
acid (SYED and LOEXHE, 1972) and returned to the bacteriology laboratory. The plaque was dispersed 
by ultra-sound for 10 set using a Sonifier micro-tip with a setting of 6 (Heat Systems-Ultrasonic Inc.) 
and then introduced into an anaerobic chamber where it was serially diluted in the RTF and appropriate 
dilutions plated on Sabouraud agar and MM10 medium (LOESCHE, HOCKETT and SYED, 1972) with 
and without 0.05 per cent kanamycin sulphate. The MM10 medium is a 0.2 per cent trypticase, 
0.05 per cent yeast extract, 2 per cent sheep blood medium supplemented with the known nutrient 
requirements of the oral flora. The Sabouraud plates were removed from the chamber and incubated 
aerobically. The yeast colonies, which grew on these plates after several days of incubation, were 
counted and recorded per mg wet weight of plaque. The colonies on the MM10 medium were counted 
after 1 week. The growth on the MM10 medium without kanamycin reflected the total viable count 
of the plaque samples, whereas the growth on the MM10 medium with kanamycin represented the 
number of colony forming units which were resistant to l/lOOth of the clinical dose of kanamycin. 
The kanamycin-resistant colonies were recorded either as the number of colony forming units per mg 
plaque wet weight, or as a percentage of the viable count. This level of kanamycin, i.e. 0.05 per cent, 
was chosen, so that if drug-resistant organisms increased in the cultures, there would still be a margin of 
safety in the in vivo situation, where 5 per cent kanamycin was used. Thus the clinical trial could be 
suspended prior to the appearance of clinical symptoms. 
The tongue swabs were manipulated on the bench top. The tube containing the swab was agitated 
for 30 set with a Vortex Mixer and then serially diluted in the RTF. Samples of 0.05 ml were plated on 
the Sabouraud and MMIO-0.05 per cent kanamycin media and the plates were incubated aerobically 
and anaerobically respectively. The number of colony-forming units were reported on a per tongue 
swab basis. 
Treatment schedule 
The subjects were seen at 5 week intervals. At the initial visit (” 0 week” in Tables), plaque and gingi- 
vitis scores and plaque wet weight were determined. The subjects were given an oral prophylaxis 
within the next few days which included some subgingival scaling. The attendants in their wards were 
instructed not to brush the teeth of these children. The subjects were randomly assigned to the two 
treatment groups, i.e. 5 per cent kanamycin (kanamycin sulphate, Bristol Laboratory, Syracuse, 
N.Y.) in Orabase (Davies Rose Hoyt, Needham, Mass.) or Orabase alone. The scores obtained from 
the 0 time exam showed that the groups were similar in regard to plaque wet weight, unstained plaque 
score, and gingivitis score, Tables 2-4. After 5 weeks, the children returned to the clinic and the 
various parameters were measured. These values reflected changes due to the prophylaxis, and also 
gave an indication of the amount of plaque that formed in 5 weeks without brushing. At this visit, 
each subject was given either one of the two treatments on a double-blind basis. The drug or placebo 
paste was applied with a cotton applicator to the buccal and labial dental-gingival surfaces in the 
morning and evening for 5 consecutive days. Two members of the investigating team applied all the 
treatments during the course of the study. The taste of the Orabase Emollient and the method of 
application were well accepted by all but one subject. Approximately 1.0 g of kanamycin sulphate per 
treated subject was administered during this 5-day-period. The subjects were seen in the clinic 5 weeks 
later, and the gingivitis and unstained plaque scores and plaque wet weight were determined. The 
treatment was decreased to nine applications, and the children were re-examined in 5 weeks. This 
5 week cycle was repeated six more times, the only change being a reduction in treatment to three 
applications, which were given on three consecutive evenings. After week 15, the children in the 
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1.8 & 0.3 2.1 rt 0.3 
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1.4 f 0.3 
I.4 5 0.4 
;:: 2 ;:: 
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1.3 + 0.3 2 1.4 7 + * 0.1 
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‘it 3,:: 
2.0 f 0.3 
NSt 
NS 
p < 0.01 
p < 0.01 
;: 
NS 
* Student f-test. 
t NS-no significant. 
$ Average plus or minus standard deviation. 
placebo group also received kanamycin therapy. At week 40, plaque was removed from the upper 
right first premolar, the upper right central incisor, the upper left first molar, the lower left fist 
premolar, the lower left central incisor and the lower right first molar in children who had been on 
kanamycin since week 5. These teeth had not been mechanically cleaned since the prophylaxis at the 
beginning of the study and the weight obtained reflected the amount of plaque which had accumulated 
during the 35-week-period of kanamycin treatment. At week 45, the treatment was omitted to deter- 
mine if there would be a rebound in plaque formation. The subjects were not observed in the between 
visit period except for random visits to the wards to reinforce the “no toothbrushing” instructions. 
To the best of our knowledge, the subjects’ teeth were not brushed during this 52-week-period. 
Exceptions might have occurred, however, if the subjects went home for short visits. 
Time in Placebo Significance* 
weeks after Kanamycin kanamycin kanamycin vs 
prophylaxis group group placebo 
0 
5 




1:2 -I- 0.3 
1.8 ‘&%3 i 0.4 
2.0 z!r 0.5 
Kanamycin 
1:: : t: ‘1:; $ “0::: 
1.1 * 0.4 1.6 f 0.4 
1.5 * 0.3 
1.5 f 0.3 
1.7 * 0.3 
No drug 




p < 0.05 
p < 0.05 
NS 
* Student t-test 
t Not significant. 
: Average plus or minus standard deviation. 
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RESULTS 
The subjects had an unstained plaque score (UPS) of 2.1 rt 0.6 and a gingivitis 
score (GS) of 2.0 & 0.6 at the initial visit (0 week). The pooled plaque removed from 
the six reference teeth averaged 22.4 rt 16.0 mg wet weight. This amount of plaque 
can be easily removed and weighed, with any loss in weight due to manipulation of the 
sample comprising a small percentage of the total plaque weight. The amount of 
plaque removed per tooth was determined, and correlation matrices were calculated 
between this value and either the UPS or GS. The correlation between wet weight and 
the UPS for five to six measurements on each of the subjects obtained during the 
course of the investigation is shown in Fig. 1. The correlation was highly significant 
with an I’ value of 0.84 over the range of 1.0-3.0 on the UPS scale. This would seem 
to indicate that, when the plaque index was modified to include an approximation 
of the amount of plaque removed from a tooth by a scaler, a reliable estimate of the 
plaque wet weight can be obtained. One unit in the UPS range of 1.0-3.0 was equiva- 
lent to about 4 mg of plaque wet weight. Our subjects never exhibited an UPS below 
1.0, presumably because their teeth were not being brushed. The GS at each 5-week 
period correlated significantly with the plaque wet weight with the 95 per cent confi- 
dence limit for I’ falling in the range from 0.42 to 0.9. When the UPS and the GS were 
compared at each 5-week period with each other, the correlation coefficient also was 
significant, i.e. the 95 per cent confidence limit for r fell in the range of 0.55-0.85. 
These data show that the modified UPS and GS were in agreement with the objective 
weight measurement and would indicate the reliability of these clinical scores in 
evaluating plaque mass in the present investigation. 
The subjects differed in the amount of plaque which they formed in the 5 weeks 
after the prophylaxis (Table 1). Two subjects were low plaque formers as only 0.5 mg 
plaque per reference tooth was found. Twelve subjects were moderate to heavy plaque 
formers with 1.6-7.2 mg plaque recovered per reference tooth. One subject was a rapid 
calculus former; his tooth surface deposits, including calculus, averaged 17.2 mg/ 
tooth. This distribution pattern suggested that at least three types of plaque formers 
were present in our sample. The subsequent clinical response to the placebo and 
kanamycin pastes bore this out. The low plaque formers had about 0.5 mg plaques 
tooth at each of the succeeding 5-week intervals, indicating that neither the “no 
brushing” regime nor the treatment had an effect on the amount of plaque formed in 
these individuals. These subjects were excluded from the calculations (one subject was 
present in each group) because they did not possess the clinical problem, i.e. heavy 
plaque formation against which the therapy was directed. At the other end of the 
distribution was the boy who was a rapid calculus former. His tooth surface deposits 
were 10 mg/tooth more than the next highest plaque former. Kanamycin treatment 
reduced these deposits by about 65 per cent, but did not prevent calculus formation. 
Even so, this subject averaged 4-5 mg plaque/tooth more than the other kanamycin 
treated subjects. He appeared to be an exceptional case not belonging to the rest of 
the study population. For this reason, it seemed justified to omit his data from the 
subsequent calculations and postulate that kanamycin might not be as effective in 
the management of oral health in those individuals who are rapid calculus formers. 
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Thus the results which follow were confined to those subjects who were moderate to 
heavy plaque-formers. The amount of plaque in this population averaged about 
3.2 mg/tooth and exhibited a distribution curve which was skewed to the right or 
high side. 
The effect that topical kanamycin had on 5-week-old plaque accumulations is 
shown in Table 2. At 0 time, the group destined to receive kanamycin averaged 
2.9 & 1% mg plaque wet weight per reference tooth, whereas the placebo group 
averaged 36 f 2.0 mg plaque wet weight. An oral prophylaxis was given, and when 
the subjects returned 5 weeks later, no change in the plaque weight was noted. The 
kanamycin and placebo pastes were then applied in a double-blind procedure, and it 
was noted that some children showed an immediate clinical improvement. Five weeks 
later, when the subjects were re-examined, one group averaged I.4 & 0.6 mg plaque/ 
tooth and the other group averaged 4.1 i 1.7 mg. This intergroup difference was 
highly significant, (i.e. Student t-test, p < O.Ol), the group showing the improve- 
ment containing those children who had shown the immediate response. The code was 
broken, and these children were found to be the recipients of the kanamycin paste. 
Kanamycin treatment in these subjects thus had reduced the 5-week plaque mass by 
about 50 per cent when compared to this group’s own pretreatment values. All of the 
subjects were retreated with nine applications of the respective pastes. Again, 5 weeks 
later, the kanamycin group showed a significant reduction when compared with the 
placebo group. The gingival condition of some children in the placebo group had 
deteriorated to pre-prophylactic levels, and a decision was made to treat this group 
also with kanamycin. At week 20, with all subjects receiving kanamycin, there was 
no difference between the groups. However, the pre- and post-treatment values for 
the former placebo group, i.e. 3.9 f I.4 mg plaque wet weight vs I.6 i 0.1 mg 
plaque wet weight were significantly different, i.e. p < 0.05. In subsequent weeks, the 
number of treatments was gradually reduced from nine to three without any loss of 
treatment effect. After week 30, the subjects were considered as a single group and 
were maintained on only three applications of kanamycin every 5th week until week 
45. At this visit, no treatment was given and, when the subjects were examined at week 
52, their plaque accumulations had returned to pre-kanamycin levels (Table 2). 
The effect of topical kanamycin on the UPS essentially paralleled its effect on the 
plaque wet weight and is shown in Table 3. The prophylaxis had no discernible effect 
on the UPS. When kanamycin was applied after week 5 to the kanamycin group or 
after week 15 to the placebo group, a 20-30 per cent reduction in UPS occurred. Thus 
in the former group the UPS dropped from I.8 & 0.3 at week 5, to 1.4 * O-3 at week 
10, and in the latter group from 2.1 i 0.3 at week 15 to I.4 f O-1 at week 20. When 
antibiotic treatment was stopped, there was an increase in the UPS at week 52. 
The GS differed from the wet weight measurement and the UPS in showing a 
residual effect of the prophylaxis (Table 4). The GS in the kanamycin group dropped 
from I.8 i 0.4 just prior to the prophylaxis to 1.5 & 0.5, 5 weeks after the prophy- 
laxis. The kanamycin treatment then lowered the GS even further, so that scores of 
1.1 It 0.3 and 1.1 f 0.4 were observed at weeks 25 and 30. Thereafter, the GS 
increased at week 35, primarily due to the transfer of two subjects who had low GS 
1138 W. J. LOEKHE AND D. NAFE 
to another institution. In the placebo group, the GS dropped from 2.3 & O-5 to 
1.7 -& O-3 as a result of the prophylaxis. In subsequent weeks, the GS increased with a 
value of 2-O & 05 recorded at week 15. This GS was significantly higher than the 
l-2 & 0.3 value recorded in the kanamycin group (Student t-test, p = 0.02). Because 
of the obvious clinical difference in the gingival health of the two groups, it seemed, 
for ethical reasons, unwarranted to continue the placebo treatment. The placebo 
subjects were given kanamycin and a gradual reduction in the GS over the next 10 
weeks was observed. This reduction was not so impressive as compared to the effect 
that the kanamycin had on supragingival plaque wet weight and on the UPS. After 
kanamycin treatment was stopped, the GS also increased at week 52. 
The data, thus far, were derived from the six reference teeth which had their 
supragingival plaque removed at each 5-week interval. The other teeth in the mouth 
appeared to show the same improvement as a result of kanamycin treatment as did 
these reference teeth. To substantiate this impression, the six opposite teeth, which 
Time after prophylaxis 0 week? 5 weekst 40 weeks: 
Plaque wet weight per tooth (mg) 3.1 + 1.7: 3.1 * 1.1 
Gingivitis score 1.9 * 0.4 1.5 * 0.4 
* Average plus or minus standard deviation. 
t Values derived from teeth 3, 9, 12, 19, 25, 28. 
$ Values derived from teeth 5, 8, 14, 21, 24, 30 
corresponded to the reference teeth, were examined for plaque wet weight and 
gingivitis scores after having gone 40 weeks without brushing. These teeth averaged 
about 2 mg plaque wet weight and had an average gingivitis score of 1.5 (Table 5). 
This plaque weight was about l-2 mg less than usually found on unbrushed teeth 
in this population (Tables 2 and 5). The GS was similar to that found 5 weeks after 
the prophylaxis in the reference teeth (Table 5) and suggested that the gingival condi- 
tion about these unbrushed teeth had not deteriorated in the subsequent 35 weeks of 
no oral hygiene. For comparison, the comparable teeth in the placebo group had gone 
from a GS of 1.7, 5 weeks after the prophylaxis to a GS of 2.0, 15 weeks after the 
prophylaxis (Table 4). 
Repeated applications of any chemotherapeutic agent raise the possibility of the 
emergence of drug-resistant organisms and/or superinfection with yeast (SENECA, 
1971; MITCHELL et al., 1967). During the course of this investigation, the yeast and the 
kanamycin-resistant bacteria present in plaque, and on the tongue, a site slightly 
removed from where the kanamycin was applied, were monitored. Table 6 shows 
that low levels of yeast were present at all times on the tongue, i.e. 7-41 x lo2 
organisms per tongue swab, and that no difference between the kanamycin and 
placebo groups could be recognized. Also the numbers of bacteria present on the 
tongue that were resistant to 0.05 per cent kanamycin did not change as a result of 
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59 12 i _C 67 10: 46 75 I_ z 51* 74 92 34 f + 34: 137* 35 11 * 43* 12
* Value obtained from subjects receiving kanamycin. 
t Plus or minus standard deviation. 
$ Placebo group received 5 per cent kanamyci” after week 15. 
kanamycin treatment. In plaque, the yeast accounted for about O-01 per cent of the 
cultivable flora and did not seem to change in number as a result of kanamycin treat- 
ment (Table 7). The number of bacteria resistant to 0.05 per cent kanamycin ranged 
from 6 to 83 x IO5 organisms/mg plaque wet weight, and represented about 6 per 
cent of the cultivable flora. Treatment with kanamycin did not increase their numbers. 
TABLE 7. EFFECT OF TCIPXXL. KANAMYCIN ON PLAQUE FLORA 
Time in weeks 




Number of yeast x lOz/mg plaque wet weight 
- 78 i 91t* 109 _L 93* 101 * 85’ 
- 31 * 12 26 + 42 66 +z 96+ ;; $ ::: 
Number of bacteria resistant to 0.05 per cent kanamycin 
counts f105/mg plaque wet weight 
83 52 + I 38’ 4 ;“9 $ gt* 31 67 f 5 42* 87 90 12 f- i 16” 83’ 
Percentage of viable bacteria resistant to 0.05 per cent kanamycin 
Treatment group 
Kanamyci” - 2.6 & 5.Ot-* 2.9 & 2.8’ I.7 * 2.0* 3.3 *1.1* 
Placebo: - 8.4 & 10.9 11.5 + 15.9 12.4 * 13.4’ 1.2 * 1.1* 
l ,Value obtained from subjects receiving kanamycin. 
t Plus or minus standard deviation. 
:iPlacebo group received 5 per cent kanamycin after wek 15. 
DISCUSSION 
The present investigation demonstrates that a topical antibiotic, such as kanamycin, 
can be used to improve the oral health of certain institutionalized Down’s syndrome 
patients. No adverse clinical signs nor emergence of antibiotic-resistant organisms 
or yeast were observed during a 52-week period of treatment and observation. These 
results support and extend the findings of MITCHELL et al. (1965, 1967) which showed 
that vancomycin applied topically could improve the oral health of anterior teeth of 
mentally retarded individuals. Together, these studies suggest that antibiotics used in 
certain situations may be of value in dental therapy. 
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The use of antimicrobial agents in plaque control raises questions concerning (1) 
the clinical condition which should be treated, (2) the delivery of these agents to the 
plaque, and (3) the reasons why certain agents may be effective. The present investi- 
gation provides some guidelines which might help to formulate the most reliable and 
successful treatment approach possible. 
The first consideration in the usage of antimicrobial agents is the selection of the 
disease situation to be treated. In medicine, antibiotics are used to treat and cure 
infections of bacterial aetiology. They have limited usefulness as prophylactic agents 
except in those situations where a high incidence of infection can be expected, e.g. 
bacteraemias following oral surgery, bowel surgery, etc., but, even here their value is 
equivocal (JOHNSTONE, 1963; KARL, MERTZ and VEITH, 1966). In dentistry, when 
antibiotics were used to treat heavy plaque accumulations and associated gingivitis, 
they appeared to be successful, whether they were topically applied, e.g. vancomycin 
(MITC~IELL and HOLMES, 1965; MITCHELL et al., 1967), kanamycin (LOESCHE et al., 
1971), or given systemically, e.g. spiromycin (DALIGAND, 1958; HARVEY, 1961 ; 
WINER, COHEN and CHAUNCEY, 1966). However, when antibiotics were given prophy- 
lactically to prevent plaque formation on teeth that apparently did not exhibit 
periodontal involvement, the results have been equivocal (Lij~ et al., 1967; JENSEN 
et al., 1968; VOLPE et al., 1969; STALLARD et al., 1969; LOBENE, BRION and SOCRANSKY, 
1969; MCFALL, 1968). This failure of antibiotics to prevent plaque formation in 
normal volunteers, who have refrained from toothbrushing during the experimental 
period, and the possibility of increased plaque formation (JENSEN et al., 1968 ; LOBENE 
et al., 1969) have obscured the potential value of these agents in the far different 
situation that exists where periodontal disease is unchecked, such as occurs in the 
mouths of handicapped individuals. Yet, even in a population of handicapped persons, 
there will be individuals who do not need treatment because they do not have a disease 
condition, i.e. low plaque formers in the present study, and others, such as the subject 
who was a rapid calculus former, whose condition might be refractory to the agent 
chosen. Conceivably for calculus formers, the drug designated as CC10232 which has 
been reported as capable of reducing calculus formation (VOLPE et al., 1969; STALLARD 
et al., 1969) might have been the agent of choice. From this it is apparent that some 
degree of clinical diagnosis and selection of drugs is necessary for optimal results with 
antibiotics. However, the chlorhexidine studies (Lij~ and RINDOM SCHIOTT, 1970; 
Lij~, 1970) suggest that a single antimicrobial agent, if it is immediately bactericidal, 
broad-spectrum and capable of adsorption to dental structures (ROLLA, LijE and 
RINDOM SCHIOTT, 1971), may overcome the problems inherent in matching the 
diseased situation with the most efficacious antibiotic. Chlorhexidine has been used 
for the prevention of supragingival plaque in “super clean” dental student volunteers 
(Lij~ and RINDOM SCHIOTT, 1970). Its efficacy in the treatment of pre-existing 
periodontal conditions has not been reported, although FLOTRA et al., (1972) noted 
that where periodontal pockets of 3 mm or more were present, chlorhexidine was not 
effective in reducing the gingivitis. The failure in this case may be attributed to the 
inability of the chlorhexidine to penetrate the pocket depth, which is a failure of the 
delivery system and not necessarily the agent. 
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Future studies of antimicrobial agents for plaque control should give high priority 
to the delivery of the agent to both supra and subgingival plaque for time periods 
adequate for optimal antibacterial action to occur. In the present study, the kanamycin 
paste was easily delivered to the supragingival areas by a cotton swab and had a 
profound effect on the subsequent mass of plaque which reformed in these sites. This 
manner of delivery would not reliably bring the kanamycin into contact with the 
subgingival plaque and, accordingly, the subgingival organisms were not inhibited to 
the same extent as the supragingival bacteria. Thus the subgingival plaque flora was 
undertreated, which could (1) account for the inability of the kanamycin to reduce the 
GS below 1.0, and (2) provide a reservoir of organisms which could recolonize the 
supragingival areas. The problem of gaining access to the subgingival plaque may be 
solved by combining topical antibiotic treatment with either mechanical pocket 
elimination as done by conventional periodontal procedures, or with systemic anti- 
biotics. The choice of drugs, dosage and dose schedule will require empirical verification 
in order to obtain optimal clinical results. 
The reasons for the residual effect of the kanamycin upon the supragingival plaque 
merits some attention. It is understandable that during the course of treatment the 
immediate reduction in plaque mass was due to the bactericidal effect of kanamycin on 
the plaque bacteria. When kanamycin was stopped, the plaque reformed, but it did 
not after 5 weeks reach the same bulk as was found previously in the pretreatment 
periods, or as was found in the placebo group. If it were simply a physical reduction in 
plaque that occurred during the period of kanamycin treatment, then the regrowth of 
plaque should have exhibited the same kinetics as that which followed the prophylaxis. 
This was not the case, as the prophylaxis had no discernable effect on 5-week plaque 
accumulations, indicating that, whatever alterations the prophylaxis caused in the 
microbial ecology of the supragingival plaque, they were of short duration. This would 
suggest that somehow the kanamycin had a persistent effect upon the plaque microbial 
ecology. This could come about if the kanamycin suppressed or eliminated certain 
bacterial species which contributed in unique ways to plaque bulk. This could be 
accomplished if the supragingival plaque contained bacteria such as Streptococcus 
mutans (GIBBONS et al., 1966), Actinomyces viscosis (JORDAN and KEYES, 1964), 
Actinomyces naeslundii (SOCRANSKY et al., 1970) or other diptheroids (HAGEAGE, 
JOHANSSEN and TANZER, 1970) which contributed, by the elaboration of an extracellular 
matrix, to plaque formation andbulk. With time, this residual kanamycin effect disap- 
peared, as was seen by the regrowth of plaque at week 52 following 12 weeks of no 
treatment. This regrowth would suggest that the organism(s) responsible for plaque 
bulk had regained dominance either through recolonization from areas of the mouth 
from which they were not eliminated, i.e. subgingival plaque, or through re-infection 
from other children in the ward. 
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Resume-Un petit groupe de malades avec le syndrome de Down, intern&, ont ete 
trait& avec la pate a sulphate de kanamycine, une ou deux fois par jour pendant 
3-5 jours, chaque 5eme semaine sur une ptriode de 52 semaines. Le poids humide de la 
plaque supragingivale dans le groupe traitt avec kanamycine Ctait significativement plus 
bas compare avec la plaque supragingivale formee dans le groupe recevant une pate 
temoin. Le nombre de gingivites dans le groupe traite avec kanamycine ne montra 
aucune deterioration pendant la periode de l’administration antibiotique, en d&pit de 
l’absence des procedes d’hygibne orale. Pendant la periode de traitement avec kanamycine 
on n’a pas d&&e une augmentation des batteries resistantes ou des levures, dans les 
echantillons de la plaque ou de la langue. 
Zusammenfassung-Eine kleine Gruppe von unter dem Down’s Syndrom leidenden 
Anstahs-Patienten wurden mit iirtlich aufgetragener Kanamycin-Sulphat-Salbe einmal 
oder zweimal tiiglich fiir 3-5 Tage behandelt, und zwar in jeder ftinften Woche wlhrend 
eines Zeitraums von 52 Wochen. Wahrend dieser 52 Wochen wurden die Zlhne nicht 
gebiirstet. Das Nassgewicht des Gaumenbelags war bei der mit Kanamycin behan- 
dehen Gruppe wesentlich herabgesetzt im Vergelich zu der mit einer simulierten Salbe 
behandelten Gruppe. Die Zahl der Entziindungen in der mit Kanamycin behandelten 
Gruppe stieg wahrend der antibiotischen Behandlung nicht an trotz der Abwesenheit 
von mundhygienischen Massnahmen. Ebenso wurde eine Erhijhung von Kanamycin 
widerstehenden Bakterien oder Pilzen bei den Belag- oder Zungentests wahrend der 
Kanamycin Behandlungsperiode nicht festgestellt. 
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